Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Mutational spectrum of myeloid malignancies with inv(3)/t(3;3) reveals a predominant involvement of RAS/RTK signaling pathways
Stefan Gröschel, Mathijs A. Sanders, Remco M. Hoogenboezem, et al.
Blood (2014) Vol. 125, Iss. 1, pp. 133-139
Open Access | Times Cited: 93

Showing 1-25 of 93 citing articles:

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Döhner, Elihu H. Estey, David Grimwade, et al.
Blood (2016) Vol. 129, Iss. 4, pp. 424-447
Open Access | Times Cited: 5160
Genomic Classification and Prognosis in Acute Myeloid Leukemia
Elli Papaemmanuil, Moritz Gerstung, Lars Bullinger, et al.
New England Journal of Medicine (2016) Vol. 374, Iss. 23, pp. 2209-2221
Open Access | Times Cited: 3546
Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance
David Grimwade, Adam Ivey, Brian J.P. Huntly
Blood (2015) Vol. 127, Iss. 1, pp. 29-41
Open Access | Times Cited: 400
Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia
Sheng Li, Francine E. Garrett-Bakelman, Stephen S. Chung, et al.
Nature Medicine (2016) Vol. 22, Iss. 7, pp. 792-799
Open Access | Times Cited: 351
Uncovering novel mutational signatures by de novo extraction with SigProfilerExtractor
S. M. Ashiqul Islam, Marcos Díaz‐Gay, Yang Wu, et al.
Cell Genomics (2022) Vol. 2, Iss. 11, pp. 100179-100179
Open Access | Times Cited: 233
Comprehensive mutational profiling of core binding factor acute myeloid leukemia
Nicolas Duployez, Alice Marceau‐Renaut, Nicolas Boissel, et al.
Blood (2016) Vol. 127, Iss. 20, pp. 2451-2459
Open Access | Times Cited: 219
The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia
A-K Eisfeld, Krzysztof Mrózek, Jessica Kohlschmidt, et al.
Leukemia (2017) Vol. 31, Iss. 10, pp. 2211-2218
Open Access | Times Cited: 90
A clinical transcriptome approach to patient stratification and therapy selection in acute myeloid leukemia
Roderick Docking, Jeremy Parker, Martin Jädersten, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 78
Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
Joshua F. Zeidner, Benjamin G. Vincent, Anastasia Ivanova, et al.
Blood Cancer Discovery (2021) Vol. 2, Iss. 6, pp. 616-629
Open Access | Times Cited: 69
Review: AberrantEVI1expression in acute myeloid leukaemia
Adil Al Hinai, Peter J.M. Valk
British Journal of Haematology (2016) Vol. 172, Iss. 6, pp. 870-878
Open Access | Times Cited: 68
EVI1 dysregulation: impact on biology and therapy of myeloid malignancies
Christine Birdwell, Warren Fiskus, Tapan M. Kadia, et al.
Blood Cancer Journal (2021) Vol. 11, Iss. 3
Open Access | Times Cited: 48
BCORgene alterations in hematologic diseases
Paolo Sportoletti, Daniele Sorcini, Brunangelo Falini
Blood (2021) Vol. 138, Iss. 24, pp. 2455-2468
Open Access | Times Cited: 42
Clinical implications of molecular markers in acute myeloid leukemia
Sabine Käyser, Mark J. Levis
European Journal Of Haematology (2018) Vol. 102, Iss. 1, pp. 20-35
Open Access | Times Cited: 59
Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors
Wei Wang, Jorge E. Cortés, Pei Lin, et al.
Blood (2015) Vol. 126, Iss. 14, pp. 1699-1706
Open Access | Times Cited: 57
Toward Individualized Therapy in Acute Myeloid Leukemia
Tapan M. Kadia, Farhad Ravandi, Jorge E. Cortés, et al.
JAMA Oncology (2015) Vol. 1, Iss. 6, pp. 820-820
Closed Access | Times Cited: 52
Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias
Brittany Knick Ragon, Hagop M. Kantarjian, Elias Jabbour, et al.
American Journal of Hematology (2016) Vol. 92, Iss. 1, pp. 7-11
Open Access | Times Cited: 49
Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2)
Guillaume Richard‐Carpentier, Caitlin R. Rausch, Koji Sasaki, et al.
Haematologica (2023)
Open Access | Times Cited: 14
GATA2 haploinsufficiency accelerates EVI1-driven leukemogenesis
S. Katayama, Mikiko Suzuki, Ayaka Yamaoka, et al.
Blood (2017) Vol. 130, Iss. 7, pp. 908-919
Open Access | Times Cited: 43
Epigenetic Guardian: A Review of the DNA Methyltransferase DNMT3A in Acute Myeloid Leukaemia and Clonal Haematopoiesis
Sabah F. Chaudry, Timothy Chevassut
BioMed Research International (2017) Vol. 2017, pp. 1-13
Open Access | Times Cited: 37
Genetic and epigenetic heterogeneity and the impact on cancer relapse
Ciaran Hassan, Ebrahim Afshinnekoo, Sheng Li, et al.
Experimental Hematology (2017) Vol. 54, pp. 26-30
Open Access | Times Cited: 34
The Interplay Between the Genetic and Immune Landscapes of AML: Mechanisms and Implications for Risk Stratification and Therapy
Lourdes M. Mendez, Ryan R. Posey, Pier Paolo Pandolfi
Frontiers in Oncology (2019) Vol. 9
Open Access | Times Cited: 31
Tumor suppressor function of Gata2 in acute promyelocytic leukemia
Casey Katerndahl, Olivia R. S. Rogers, Ryan B. Day, et al.
Blood (2021) Vol. 138, Iss. 13, pp. 1148-1161
Open Access | Times Cited: 25
Mechanisms of enhancer‐driven oncogene activation
Joyce Vriend, Ruud Delwel, Dorien Pastoors
International Journal of Cancer (2025)
Open Access
Aberrant EVI1 splicing contributes to EVI1-rearranged leukemia
Atsushi Tanaka, Taizo A. Nakano, Masaki Nomura, et al.
Blood (2022) Vol. 140, Iss. 8, pp. 875-888
Open Access | Times Cited: 15
Oncogenic Enhancers in Leukemia
Roger Mulet‐Lazaro, Ruud Delwel
Blood Cancer Discovery (2024) Vol. 5, Iss. 5, pp. 303-317
Closed Access | Times Cited: 3
Page 1 - Next Page

Scroll to top